I-SPY in the News
Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
Karyn DiGiorgio
Quantum Leap Healthcare Collaborative
karyn.digiorgio@quantumleaphealth.org